Pure Global
NCT06405542

Exercise-based Rehabilitation to Treat Persistent Chemotherapy Induced Peripheral Neuropathy (CIPN)

EX-CIPN: An Exercise-based Rehabilitation Intervention to Treat Persistent Chemotherapy-Induced Peripheral Neuropathy (CIPN)
University Health Network, Toronto·Phase 1·ClinicalTrials.gov·behavioralRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chemotherapy-induced Peripheral Neuropathy
Drug/Device/Intervention
EX-CIPN
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
University Health Network, Toronto
Location
Toronto, Canada
Timeline & enrollment
Phase
Phase 1
Start date
Apr 25, 2024
End date
Jul 01, 2025
Enrollment
40 participants
Primary outcome

Accrual Rate,Retention Rates,Adherence,Intervention Safety

Summary

The goal of this clinical trial is to learn if the EX-CIPN exercise-based intervention is
 feasible, acceptable, and safe in participants with persistent chemotherapy-induced
 peripheral neuropathy (CIPN). It will also give insight on the effectiveness of the exercise
 intervention in treating CIPN symptoms. The main questions it aims to answer are:
 
 - Is EX-CIPN safe, acceptable, and feasible in cancer survivors experiencing persistent
 CIPN?
 
 - Are the study design and methods feasible (recruitment and retention rates, feasibility
 of data collection and procedures)?
 
 Researchers will provide all participants with the exercise-based intervention.
 
 Participants will:
 
 - Complete assessments at baseline, immediately post-intervention, and 3-months
 post-intervention
 
 - Complete a 10-week remote, individualized exercise program
 
 - Receive health coaching calls on weeks 2, 3, 4, 6, and 8 of the intervention
 
 - Wear a FitBit throughout the study to track physical activity and promote behaviour
 change

ICD-10 classifications
Drug-induced polyneuropathyParaneoplastic neuromyopathy and neuropathyPolyneuropathy due to other toxic agentsIdiopathic peripheral autonomic neuropathyIdiopathic progressive neuropathy
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06405542
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06405542 through Pure Global AI's free database. This Phase 1 trial is sponsored by University Health Network, Toronto and is currently Recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.